!

COVID-19 Response

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Baylor College of Medicine

AMC-098: Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma (H-44430)

Description

Content

AMC-098: A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma

PURPOSE: This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

For more information: https://clinicaltrials.gov/ct2/show/NCT03077451

Contact

Dr. Elizabeth Chiao

Phone 1: 713–794–8666

IRB: H-44430

Status:

Active

Created:

Back to topback-to-top